Teva Pharmaceutical Industries Limited (TEVA) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$36.34
Price Target
$39.00
Target Range
$35.00 — $42.00
Analyst Rating
Buy
Forward P/E14.7x
Trailing P/E30.3x
Forward PEG—
Implied Growth+86.6%
Median Target$40.00
Analyst Spread17.9%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$35
-3.7%
Consensus
$39
+7.3%
Bull Case
$42
+15.6%
TEVA Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Teva Pharmaceutical Industries Limited (TEVA) has a Wall Street consensus price target of $39.00, based on estimates from 46 covering analysts. With the stock currently trading at $36.34, this represents a potential upside of +7.3%. The company has a market capitalization of $42.31B.
Analyst price targets range from a low of $35.00 to a high of $42.00, representing a 18% spread in expectations. The median target of $40.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 22 analysts rating the stock as a Buy or Strong Buy,20 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, TEVA trades at a trailing P/E of 30.3x and forward P/E of 14.7x. Analysts expect EPS to grow +86.6% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+17.9%
Avg Forward P/E14.4x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 VTRSViatris Inc. | $18.4B | $15.95 | $15.25 | -4.4% | Hold | 6.5x | 12 |
 PRGOPerrigo Company plc | $1.7B | $12.26 | $20.00 | +63.1% | Hold | 5.8x | 36 |
 AMRXAmneal Pharmaceuticals, Inc. | $4.3B | $13.62 | $17.00 | +24.8% | Buy | 13.7x | 16 |
 SUPNSupernus Pharmaceuticals, Inc. | $3.0B | $51.45 | $60.00 | +16.6% | Buy | 23.7x | 14 |
 LNTHLantheus Holdings, Inc. | $5.6B | $86.15 | $101.00 | +17.2% | Buy | 16.6x | 17 |
 PAHCPhibro Animal Health Corporation | $2.4B | $58.64 | $49.00 | -16.4% | Buy | 19.3x | 13 |
 MCKMcKesson Corporation | $91.1B | $743.67 | $1006.50 | +35.3% | Buy | 19.1x | 31 |
 CAHCardinal Health, Inc. | $45.1B | $191.49 | $249.67 | +30.4% | Buy | 18.5x | 33 |
 CVSCVS Health Corporation | $111.3B | $86.86 | $95.20 | +9.6% | Buy | 12.1x | 41 |
 PFEPfizer Inc. | $150.8B | $26.50 | $27.27 | +2.9% | Hold | 9.0x | 39 |
Upside Potential Comparison
PRGOMCKCAHAMRXLNTHSUPNCVSPFEFull TEVA Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See TEVA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TEVA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TEVA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTEVA — Frequently Asked Questions
Quick answers to the most common questions about buying TEVA stock.
What is the TEVA stock price target for 2026?
The consensus price target for TEVA is $39, close to the current price of $36.335 (7.3% implied move). Based on 46 analyst estimates, the stock appears fairly valued near current levels.
Is TEVA a buy, sell, or hold?
TEVA has a consensus rating of "Buy" based on 46 Wall Street analysts. The rating breakdown is mixed, with 20 Hold ratings making up the largest segment. The consensus 12-month price target of $39 implies 7.3% upside from current levels.
Is TEVA stock overvalued or undervalued?
With a forward P/E of 14.6767x, TEVA trades at a relatively low valuation. The consensus target of $39 implies 7.3% appreciation, suggesting the market may be pricing in risks.
How high can TEVA stock go?
The most bullish Wall Street analyst has a price target of $42 for TEVA, while the most conservative target is $35. The consensus of $39 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover TEVA stock?
TEVA is heavily covered by Wall Street, with 46 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 22 have Buy ratings, 20 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the TEVA stock forecast?
The 12-month TEVA stock forecast based on 46 Wall Street analysts shows a consensus price target of $39, with estimates ranging from $35 (bear case) to $42 (bull case). The median consensus rating is "Buy".
What is TEVA's forward P/E ratio?
TEVA trades at a forward P/E ratio of 14.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 30.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy TEVA stock?
TEVA appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $39 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do TEVA price targets vary so much?
TEVA analyst price targets range from $35 to $42, a 18% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $39 consensus represents the middle ground.